FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980212997> ?p ?o ?g. }

• W2980212997 endingPage "1198" @default.
• W2980212997 startingPage "1198" @default.
• W2980212997 abstract "Abstract Abstract 1198 Poster Board I-220 Background: Unrelated cord blood transplantation is an alternative option to treat patients with high risk hematologic malignancies in the absence of an HLA identical donor. Results of UCBT in patients with MDS or secondary leukaemia (sAML) have been scarcely published. Method: We performed a survey to identify predictors of outcomes in a large cohort of 108 adults with MDS or sAML reported to Eurocord-Promise data bases (62 centres in 17 countries in Europe) and transplanted with an UCBT from 1998 to 2007. Sixty-seven patients were transplanted for sAML (secondary to MDS in 42 cases) and 41 for MDS. Worst status before UCBT for MDS was RA in 4, RAEB1 in 10, RAEB2 in 14, CMML or RAEBt in 9, unclassified in 4 patients. IPSS classification at transplantation was low, intermediate 1, intermediate 2, high or missing in 8, 12, 7, 6 and 8 patients, respectively. For patients with sAML, 48% were transplanted in CR1 at UCBT. Median age at UCBT was 43 years (from 18 to 72 years). Median time from diagnosis to UCBT was 10 months. Transplant characteristics: 77 patients received a single and 31 a double UCBT. UCB grafts had ≥ 2/6 HLA mismatched in 60 % of cases. Myeloablative conditioning regimen (MAC) was given to 57 patients whereas 51 patients received a reduced intensity conditioning regimen (RIC). GVHD prophylaxis consisted in CSA+MMF in 52, CSA+steroids in 43 and other combinations in 13 patients. Median number of collected nucleated cells was 3.4 for single and 4.6 × 107/kg for double UCBT. Median follow-up was 25 months. Results: cumulative incidence (CI) of neutrophil recovery at day 60 was 82±4% with a median time to achieve more than 500 ANC/mm3 of 23 days. Neutrophil recovery was independently associated with number of CD34+ cells/kg (> 1.1 × 105, Hazard Ratio (HR), 1.79; P= .02) and advanced disease status (intermediate 2 or high MDS and sAML not in CR; HR, 1.92; P= .007). CI of grade II-IV acute GVHD at day 100 and chronic GVHD at 2 years were 26±4% (II n=18, III n=6, IV n =6) and 42%±8, respectively. Two-year non-relapse mortality was significantly higher after MAC (62% vs. 34%, p=0.009). In counterpart, 2-year relapse rate was higher after RIC (14% vs 29%, p=0.02). Two-year DFS and OS were 30 and 34%, respectively. In univariate analysis, among patient-, disease- and transplant- factors studied only patients with high risk disease at maximal pre-transplant stage or transplanted > 18 months after diagnosis had significant poorer DFS (disease risk: 49% vs. 22%; time: 35% vs. 15%). However, in multivariate analysis, the only factor associated with decreased DFS was advanced disease (HR: 2.05; p= .01). Conclusion: These data indicate that UCBT is an acceptable alternative option to treat adults with high risk MDS or sAML without a HLA-matched related or unrelated bone marrow donor. Controlled disease at time of transplantation improves outcome. More investigations are needed to compare these results with outcomes after other stem cell sources from unrelated HSCT donor. Disclosures: No relevant conflicts of interest to declare." @default.
• W2980212997 created "2019-10-18" @default.
• W2980212997 creator A5000080683 @default.
• W2980212997 creator A5001526915 @default.
• W2980212997 creator A5008747694 @default.
• W2980212997 creator A5010183839 @default.
• W2980212997 creator A5024783703 @default.
• W2980212997 creator A5029260153 @default.
• W2980212997 creator A5034871851 @default.
• W2980212997 creator A5042722243 @default.
• W2980212997 creator A5049735878 @default.
• W2980212997 creator A5052934298 @default.
• W2980212997 creator A5058751095 @default.
• W2980212997 creator A5059617413 @default.
• W2980212997 creator A5078272678 @default.
• W2980212997 date "2009-11-20" @default.
• W2980212997 modified "2023-09-29" @default.
• W2980212997 title "Unrelated Cord Blood Transplantation (UCBT) in Adults with MDS or Secondary Acute Myeloblastic Leukemia (sAML): a Survey On Behalf of Eurocord and CLWP of EBMT." @default.
• W2980212997 doi "https://doi.org/10.1182/blood.v114.22.1198.1198" @default.
• W2980212997 hasPublicationYear "2009" @default.
• W2980212997 type Work @default.
• W2980212997 sameAs 2980212997 @default.
• W2980212997 citedByCount "0" @default.
• W2980212997 crossrefType "journal-article" @default.
• W2980212997 hasAuthorship W2980212997A5000080683 @default.
• W2980212997 hasAuthorship W2980212997A5001526915 @default.
• W2980212997 hasAuthorship W2980212997A5008747694 @default.
• W2980212997 hasAuthorship W2980212997A5010183839 @default.
• W2980212997 hasAuthorship W2980212997A5024783703 @default.
• W2980212997 hasAuthorship W2980212997A5029260153 @default.
• W2980212997 hasAuthorship W2980212997A5034871851 @default.
• W2980212997 hasAuthorship W2980212997A5042722243 @default.
• W2980212997 hasAuthorship W2980212997A5049735878 @default.
• W2980212997 hasAuthorship W2980212997A5052934298 @default.
• W2980212997 hasAuthorship W2980212997A5058751095 @default.
• W2980212997 hasAuthorship W2980212997A5059617413 @default.
• W2980212997 hasAuthorship W2980212997A5078272678 @default.
• W2980212997 hasConcept C126322002 @default.
• W2980212997 hasConcept C141071460 @default.
• W2980212997 hasConcept C143998085 @default.
• W2980212997 hasConcept C2776694085 @default.
• W2980212997 hasConcept C2776755627 @default.
• W2980212997 hasConcept C2779263901 @default.
• W2980212997 hasConcept C2779709957 @default.
• W2980212997 hasConcept C2911091166 @default.
• W2980212997 hasConcept C71924100 @default.
• W2980212997 hasConcept C72563966 @default.
• W2980212997 hasConcept C90924648 @default.
• W2980212997 hasConceptScore W2980212997C126322002 @default.
• W2980212997 hasConceptScore W2980212997C141071460 @default.
• W2980212997 hasConceptScore W2980212997C143998085 @default.
• W2980212997 hasConceptScore W2980212997C2776694085 @default.
• W2980212997 hasConceptScore W2980212997C2776755627 @default.
• W2980212997 hasConceptScore W2980212997C2779263901 @default.
• W2980212997 hasConceptScore W2980212997C2779709957 @default.
• W2980212997 hasConceptScore W2980212997C2911091166 @default.
• W2980212997 hasConceptScore W2980212997C71924100 @default.
• W2980212997 hasConceptScore W2980212997C72563966 @default.
• W2980212997 hasConceptScore W2980212997C90924648 @default.
• W2980212997 hasIssue "22" @default.
• W2980212997 hasLocation W29802129971 @default.
• W2980212997 hasOpenAccess W2980212997 @default.
• W2980212997 hasPrimaryLocation W29802129971 @default.
• W2980212997 hasRelatedWork W1973417241 @default.
• W2980212997 hasRelatedWork W2537155420 @default.
• W2980212997 hasRelatedWork W2552185487 @default.
• W2980212997 hasRelatedWork W2552794718 @default.
• W2980212997 hasRelatedWork W2563099149 @default.
• W2980212997 hasRelatedWork W2563788622 @default.
• W2980212997 hasRelatedWork W2570440116 @default.
• W2980212997 hasRelatedWork W2572644617 @default.
• W2980212997 hasRelatedWork W2580006679 @default.
• W2980212997 hasRelatedWork W2580770276 @default.
• W2980212997 hasRelatedWork W2590834799 @default.
• W2980212997 hasRelatedWork W2591670358 @default.
• W2980212997 hasRelatedWork W2979648184 @default.
• W2980212997 hasRelatedWork W2980383141 @default.
• W2980212997 hasRelatedWork W2981097127 @default.
• W2980212997 hasRelatedWork W2981145619 @default.
• W2980212997 hasRelatedWork W2991819990 @default.
• W2980212997 hasRelatedWork W2992525088 @default.
• W2980212997 hasRelatedWork W3002815227 @default.
• W2980212997 hasRelatedWork W3175043291 @default.
• W2980212997 hasVolume "114" @default.
• W2980212997 isParatext "false" @default.
• W2980212997 isRetracted "false" @default.
• W2980212997 magId "2980212997" @default.
• W2980212997 workType "article" @default.